 MARSEILLE, France--BUSINESS WIRE--Regulatory News: Innate Pharma SA Euronext Paris: IPH; Nasdaq: IPHA Innate or the Company today announced that the following presentations will be presented at the ESMO European Society for Medical Oncology Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsedrefractory peripheral T-cell lymphoma that express KIR3DL2 - A 